Kusal Weerasinghe

Background: The integration of artificial intelligence (AI) into healthcare research has the potential to enhance research capacity, streamline protocol development, and reduce barriers to engagement. Medway NHS Foundation Trust identified a plateau in homegrown research participation, particularly among clinicians with limited research experience. A generative AI-driven chatbot was introduced to assist researchers in protocol development by providing step-by-step guidance, prompting ethical and scientific considerations, and offering immediate feedback. Methods: The chatbot was developed using OpenAI’s GPT-3.5 architecture, customised with domain-specific training based on Trust guidelines, Health Research Authority (HRA) requirements, and Integrated Research Application System (IRAS) submission protocols. It was deployed to guide researchers through protocol planning, ensuring compliance with ethical and scientific standards. A mixed-methods evaluation was conducted using a qualitative-dominant sequential explanatory design. Seven early adopters completed a 10-item questionnaire (5-point Likert scales), followed by eight free-flowing interviews to achieve thematic saturation. Results: Since its launch, the chatbot has received an overall performance rating of 8.86/10 from the seven survey respondents. Users reported increased confidence in protocol development, reduced waiting times for expert review, and improved inclusivity in research participation across professional groups. However, limitations in usage due to free-tier platform constraints were identified as a key challenge. Conclusions: AI-driven chatbot tools show promise in supporting research engagement in busy clinical environments. Future improvements should focus on expanding access, optimising integration, and fostering collaboration among NHS institutions to enhance research efficiency and inclusivity.

The integration of artificial intelligence (AI) in ophthalmology is transforming the field, offering new opportunities to enhance diagnostic accuracy, personalize treatment plans, and improve service delivery. This review provides a comprehensive overview of the current applications and future potential of AI in ophthalmology. AI algorithms, particularly those utilizing machine learning (ML) and deep learning (DL), have demonstrated remarkable success in diagnosing conditions such as diabetic retinopathy (DR), age-related macular degeneration, and glaucoma with precision comparable to, or exceeding, human experts. Furthermore, AI is being utilized to develop personalized treatment plans by analyzing large datasets to predict individual responses to therapies, thus optimizing patient outcomes and reducing healthcare costs. In surgical applications, AI-driven tools are enhancing the precision of procedures like cataract surgery, contributing to better recovery times and reduced complications. Additionally, AI-powered teleophthalmology services are expanding access to eye care in underserved and remote areas, addressing global disparities in healthcare availability. Despite these advancements, challenges remain, particularly concerning data privacy, security, and algorithmic bias. Ensuring robust data governance and ethical practices is crucial for the continued success of AI integration in ophthalmology. In conclusion, future research should focus on developing sophisticated AI models capable of handling multimodal data, including genetic information and patient histories, to provide deeper insights into disease mechanisms and treatment responses. Also, collaborative efforts among governments, non-governmental organizations (NGOs), and technology companies are essential to deploy AI solutions effectively, especially in low-resource settings.

Background: Cancer remains a leading cause of death worldwide. Progress in its effective treatment has been hampered by challenges in personalized therapy, particularly in patients with comorbid conditions. The integration of artificial intelligence (AI) into patient profiling offers a promising approach to enhancing individualized anticancer therapy. Objective: This narrative review explores the role of AI in refining anticancer therapy through personalized profiling, with a specific focus on cancer patients with comorbid migraine. Methods: A comprehensive literature search was conducted across multiple databases, including PubMed, Scopus, and Google Scholar. Studies were selected based on their relevance to AI applications in oncology and migraine management, with a focus on personalized medicine and predictive modeling. Key themes were synthesized to provide an overview of recent developments, challenges, and emerging directions. Results: AI technologies, such as machine learning (ML), deep learning (DL), and natural language processing (NLP), have become instrumental in the discovery of genetic and molecular biomarkers of cancer and migraine. These technologies also enable predictive analytics for assessing the impact of migraine on cancer therapy in comorbid cases, predicting outcomes and provide clinical decision support systems (CDSS) for real-time treatment adjustments. Conclusions: AI holds significant potential to improve the precision and effectiveness of the management and therapy of cancer patients with comorbid migraine. Nevertheless, challenges remain over data integration, clinical validation, and ethical consideration, which must be addressed to appreciate the full potential for the approach outlined herein.

Background: Cancer remains a leading cause of death worldwide. The progress in effective treatment has been hampered by challenges in personalized therapy, particularly in patients with comorbid conditions. The integration of artificial intelligence (AI) into patient profiling offers a promising approach to enhancing individualized anticancer therapy. Objective: This narrative review explores the role of AI in refining anticancer therapy through personalized profiling, with a specific focus on cancer patients with co-morbid migraine. Methods: A comprehensive literature search was conducted across multiple databases, including PubMed, Scopus, and Google Scholar. Studies were selected based on their relevance to AI applications in oncology and migraine management, with a focus on personalized medicine and predictive modeling. Key themes were synthesized to provide an overview of recent developments, challenges, and emerging directions. Results: AI technologies such as machine learning (ML), deep learning (DL), and natural language processing (NLP) have become instrumental in discovery of genetic and molecular biomarkers to cancer and migraine. These technologies also enable predictive analytics for assessing the impact of migraine on cancer therapy in co-morbid cases, predicting outcomes and provide clinical decision support systems (CDSS) for real-time treatment adjustments. Conclusion: AI holds significant potential to improve the precision and effectiveness of cancer management and therapy, particularly for cancer patients with co-morbid migraine. Nevertheless, challenges remain over data integration, clinical validation, and ethical consideration, which must be addressed to appreciate the full potential for outlines approach.